Introduction: Polycystic ovary syndrome is one of the most common endocrine disorders in women, characterized by ovulatory dysfunction and follicular changes. It impacts oocyte quality and ART outcomes. Evidence suggests that chronic inflammation plays a significant role in PCOS pathophysiology, and elevated markers like CRP can reduce fertility outcomes. This study aimed to evaluate the effect of inositol supplementation on CRP levels and ART outcomes in women with PCOS.

Methods: A randomized clinical trial was conducted in 2023-2024 with 114 women diagnosed with PCOS who were candidates for IVF. Participants met the Rotterdam criteria, were aged 18-40, and had no chronic diseases. They were divided into two groups. The control group received metformin, while the intervention group received metformin plus inositol for at least two months prior to IVF. Oocyte retrieval, assessment of oocyte maturation, fertilization, and embryo quality were performed according to standard protocols. CRP levels were measured before the procedure and on the day of oocyte retrieval. Data were analyzed using appropriate statistical tests, with p< 0.05 considered significant.

Results: Both groups showed significant reduction in CRP, but the reduction was greater in the inositol group. The number of oocytes did not differ, but their quality, as well as the number and quality of embryos, were significantly higher in the intervention group. Regression confirmed the independent effect of inositol and CRP reduction on embryo improvement.

Conclusion: Findings indicate that the combination of inositol and metformin is a promising strategy for improving reproductive parameters in PCOS patients undergoing IVF.